☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals’ AMX0035 Gains the EC’s Orphan Drug Designation to Treat Wolfram Syndrome
August 5, 2024
Amylyx Pharmaceuticals Reports the First Patient Dosing with AMX0035 in P-III Trial for the Treatment of Progressive Supranuclear...
December 25, 2023
Amylyx Pharmaceuticals Entered into an Exclusive Distribution Agreement with Neopharm for AMX0035
January 17, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.